Academic Journal

Neuropharmacology

32 Papers Indexed in Blossom

Published Papers

Cognitive and Subjective Effects of Psilocybin Microdosing: Results from Two Double-Blind Placebo-Controlled Longitudinal Trials

This set of two randomised, double-blind, placebo-controlled trials (n=141) investigated the longitudinal effects of microdosing psilocybin truffles on cognition and well-being in semi-naturalistic settings. Contrary to anecdotal reports, the study finds no significant improvements in cognitive control, memory, social cognition, or subjective well-being compared with placebo.

Published: February 1, 2026
Journal: Neuropharmacology
Authors: Hommel, B., Kuchař, M., Lippelt, D. P., Marschall, J., Prochazkova, L., Schon, N. R.

Open Accessindividual

LSD microdosing in major depressive disorder: results from an open-label trial

This open-label Phase IIa trial (n=19, 15 male) found that an 8-week regimen of microdosed LSD (8μg initially, then 6-20μg twice weekly) for major depressive disorder was well-tolerated with no serious adverse events or cardiac valvulopathy, achieved 59.5% reduction in MADRS scores sustained for six months, and had only one withdrawal due to anxiety.

Published: February 1, 2026
Journal: Neuropharmacology
Authors: Allen, N., Alshakhouri, M., Daldegan-Bueno, D., Donegan, C. J., Evans, W. J., Forsyth, A., Hoeh, N. R., Menkes, D. B., Muthukumaraswamy, S., Ponton, R., Reynolds, L. M, Roop, P., Smith, T., Sumner, R. L., Sundram, F.

Open Accessmeta

Side Effects of Microdosing Lysergic Acid Diethylamide and Psilocybin: A Systematic Review of Potential Physiological and Psychiatric Outcomes

This systematic review (s=31) examines the side effects of microdosing LSD and psilocybin, finding that adverse effects are typically dose-dependent, mild, and short-lived. Common side effects include increased blood pressure, anxiety, and cognitive impairment. The review highlights the lack of standardised reporting on side effects and calls for future studies to provide more systematic and transparent assessments.

Published: February 26, 2025
Journal: Neuropharmacology
Authors: Lukasiewicz, K., Modzelewski, S., Stankiewisz, A., Waszkiewicz, N.

Open Accessindividual

Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication

This open-label Phase II trial (n=19) investigates the safety, tolerability, and efficacy of synthetic psilocybin (COMP360) as an adjunct to selective serotonin reuptake inhibitors (SSRIs) in adults with treatment-resistant depression (TRD). The study found no serious treatment-emergent adverse events or increased suicidal ideation. It reported a significant decrease in depression (MADRS) and Clinical Global Impression-Severity (CGI-S) scores at week 3, with response and remission observed in 42.1% of participants.

Published: July 13, 2023
Journal: Neuropharmacology
Authors: Croal, M., Feifel, D., Goodwin, G. M., Kelly, J. R., Malievskaia, E., Marwood, L., Mistry, S., O’Keane, V., Peck, S. K., Simmons, H., Sisa, C., Stansfield, S., Tsai, J., Williams, S.

Paywallmeta

Canalization and plasticity in psychopathology

This theory-building paper (2022) introduces a new model of psychopathology called canalization, which is a form of plasticity that relates to increased model precision. It suggests that TEMP, combined with psychological support, can counter the entrenchment of canalization in pathological phenotypes, and offers suggestions for experiments to test its main hypotheses and implications.

Published: March 1, 2023
Journal: Neuropharmacology
Authors: Carhart-Harris, R. L., Chandaria, S., Erritzoe, D., Friston, K. J., Gazzaley, A., Girn, M., Kettner, H., Mediano, P. A. M., Nutt, D. J., Rosas, F. E., Roseman, L., Timmermann, C., Weiss, B., Zeifman, R. J.

Open Accessmeta

More than meets the eye: The role of sensory dimensions in psychedelic brain dynamics, experience, and therapeutics

This pre-print (2022) reviews the current body of evidence surrounding the effects psychedelics have on low-level sensory dimensions of experience, and corresponding brain dynamics, particularly visual dimensions. It is proposed that psychedelic-induced alterations in low-level sensory dimensions of experience are not entirely causally reducible to alterations in high-level dimensions, but rather co-occur in a dialogical interplay and play a causally relevant role in determining high-level alterations and therapeutic outcomes.

Published: November 10, 2022
Journal: Neuropharmacology
Authors: Aqil, M., Roseman, L.

Quick Facts

Papers Indexed: 32
h-Index: 199
Open Access: No
Publisher: Elsevier
Country: United Kingdom
Website: Visit